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ABSTRACT 
In the current study a simple, precise, sensitive and accurate reversed phase liquid chromatography method was developed for the analysis and 
estimation of Lorcaserin HCL in bulk and tablet dosage form. The present study of Lorcaserin HCL was achieved by using Cosmosil C18 
(250nm×4.6ID, Particle Size: 5 Micron) Column with mobile phase Methanol:10mM KH2PO4 Buffer (70:30) pH:3 at a flow rate 0.8ml/min with 
UV detection at 222nm. The retention time for Lorcaserin HCL was found to be 5.108 min. In Linearity the correlation coefficient (R2) for 
Lorcaserin HCL was found to be 0.9995, slope is 42071 and intercept was found to be 21966 which are well within the acceptanc e criteria. The 
mean percent recovery for Lorcaserin HCL at three different levels for 50%, 100%, and 150% was found to be 100.65%, 98.84% and 100.34%. 
The %RSD (NMT 2%). In precision study interday (RSD is 0.26%) and intraday (RSD is 0.29%) are found.  Forced degradation experiments was 
carried out by exposing standard form of Lorcaserin HCL for Acid-base hydrolytic, Oxidative, photolytic and thermal stress conditions. The 
method has been validated by System suitability parameters, Linearity, Accuracy and Percent recovery, Precision, Ruggedness, Robustness, LOD 
and LOQ. 
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INTRODUCTION: 
Lorcaserin Hydrochloride is highly selective (5HT)2C 
receptor agonist, is used for the treatment of obesity. It has 
been shown to reduce body weight and it is targeting the 
(5HT)2C receptor may alter body weight by regulating 
satiety. Lorcaserin is chemically derivative of benzazepine [1]. 
Lorcaserin is also evaluated for its ability to interact with 
number of other human GPCRs and neurotransmitter 
transporters [2]. The chemical name is (5R)-7-chloro-5-
methyl-2, 3, 4, 5-tetrahydro-1H-3 benzazepine 
hydrochloride [3]. Lorcaserin is approved by many countries 
as a 10-mg tablet for BID dosing and it is indicated for long 
term weight management in adults with obesity [4]. In clinical 
trials 47.5% subjects who received 10-mg Lorcaserin once at 
daily they lost 5% or more of their body weight [5]. In 
introduction of stability indicating study, it is determine 
stability of drug substance which may affect purity potency 
and safety [6]. The values between 5% to 20% degradation of 
the drug substance considered as reasonable and acceptable 
generally for validation of chromatographic assays [7]. 
Different methods were described in the literature for the 
determination of Lorcaserin HCL in tablet and in API form. 
The techniques include validated UPLC MS/MS Assay for 
rapid determination of Lorcaserin in Plasma and brain tissue 
samples [8], Liquid chromatographic separation and 
thermodynamic investigation of Lorcaserin HCL 
enantiomers on Immobilized amylose based chiral 
stationary phase [9], development and validation of a HPLC-
based bioanalytical method for Lorcaserin using solid phase 
extraction and application to a pharmacokinetic Study in 
rats [10] and content determination of Lorcaserin HCL by 
HPLC [11]. 
However, there is no stability indicating RP-HPLC method 
reported for estimation of Lorcaserin HCL. The aim of this 
work was to develop and validate RP-HPLC stability 
indicating method for estimation and determination of 
Lorcaserin HCL in bulk and pharmaceutical dosage form. 
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Chemical Formula and Structure of Lorcaserin HCl [12]: 
C11H15CL2N 
  
Fig-1: Chemical structure of Lorcaserin HCL 
MATERIALS AND METHODS: 
Chemicals and Solvents: 
A HPLC grade Potassium dihydrogen phosphate, O-
Phosphoric acid, Methanol, Hydrogen peroxide, 
Hydrochloric acid, Sodium hydroxide and purified water 
were procured from Loba Chemie Pvt. Ltd. 
Chromatographic Conditions: 
A High Performance Liquid Chromatographic System 
(Binary Gradient System) was used for the analysis. The 
Pump P-3000-M Reciprocating (40MPa), Column Cosmosil 
C18 (250mm×4.6ID, Partical size-5 micron), Detector UV-
3000-M was used system manufactured by Analytical 
Technologies Ltd. Mobile phase containing Methanol:10mM 
KH2PO4 Buffer (70:30) pH:3 at a flow rate 0.8ml/min, 
sample volume used 20µl and pressure is 10-11MPa with UV 
detection at 222nm. 
Mobile phase preparation: 
Mixed a HPLC grade Methanol and 10mM KH2PO4 Buffer 
Solution (70:30) pH:3 in volumetric flask and filtered 
through 0.45µ filter under vacuum filtration. 
Method of preparation of 10mM KH2PO4 Buffer Solution: 
Weighed accurate 0.136g of KH2PO4 and was dissolved in 
100ml of water and pH was adjusted to 3 using o-phosphoric 
acid (qs). 
Diluent Preparation: Use Mobile phase as Diluent. 
Preparation of standard stock solution: 
Accurately weigh and transfer 10 mg of pure drug 
Lorcaserin hydrochloride in to clean and dry 10 ml 
volumetric flask. Add diluent and sonicated to dissolve it 
completely and made volume up to the mark with same 
solvent (Mobile Phase). This gives 1000 ppm solution. 
Preparation of working standard solution: 
From the above standard stock solution subsequent 
dilutions were made in mobile phase to give the 
concentrations 10, 20, 30, 40 and 50 ppm for Lorcaserin 
HCL. 
Preparation of sample stock solution: 
A sample solution of Lorcaserin HCL was prepared by using 
20 tablets of Belviq 10mg (containing 10 mg of Lorcaserin 
HCL label claim). Make fine powder of tablets by crushing to 
it. Weigh and transfer sample powder quantity equivalent to 
10 mg of Lorcaserin and dissolved in diluent. The resulting 
solution was sonicated for 15 Min the solution was filtered 
through 0.45µ membrane filter and made volume up to mark 
with mobile phase. Dilutions and final concentrations were 
made by using with mobile phase. 
Preparation of working sample solution: 
Aliquots from sample stock solution was pipetted and 
transferred in to a series of clean and dry 10 ml volumetric 
flask and diluents was added up to mark to get final 
concentration of Lorcaserin hydrochloride. 
Selection of Wavelength: 
UV spectrum of Lorcaserin diluent (Mobile phase 
composition) was recorded. From available spectrum 
wavelength selected as 222nm. At this wavelength, drug was 
showing good absorbance result of analysis is presented in 
fig.2. 
Assay: 
A 20 µL volume of these standard and sample solutions was 
used. After completion the setting of chromatographic 
conditions and stabilizing the instrument to obtain a steady 
baseline. The solution was injected and a chromatogram was 
recorded. 
The percent assay for bulk drug was calculated by using 
regression equation and peak areas of drug used for 
calculation of percent assay for formulation the results of 
analysis are presented in Table 1. 
METHOD VALIDATION: 
System suitability test: 
System suitability tests are integral part of method 
development and are used to ensure adequate performance 
of the chromatographic system shown in fig.3. The results 
given in table 2 were within acceptable limits. 
Linearity: 
The linearity of the method was determined by using a 
solution of five concentration levels ranging from 10 to 
50ppm of Lorcaserin HCL. The calibration curve was 
constructed by area against concentration of drug and it is 
shown in fig.4. The Correlation coefficient for area verses 
concentration of analyte was calculated and is presented in 
Table 3. 
Accuracy (Recovery study): 
Accuracy of the method was determined by recovery 
experiments was conducted at three different levels 50%, 
100% and 150% samples were prepared with Lorcaserin 
HCL. The recovery study calculated percentage recovery 
presented in Table 4 & 5. From the data obtained, added 
recoveries of standard drug found to be accurate. 
Precision: 
The precision of the method was determined by Interday 
and Intraday studies. In Interday studies a standard solution 
was injected for six times in two days from available data to 
calculated SD and %RSD. In Intraday studies a standard 
solution was injected for six times in same day from data to 
calculated SD and %RSD. The result shown in Table 6. 
Ruggedness: 
Ruggedness was determined by making small changes in 
flow rate and wavelength. By using a solution of five 
concentration level ranging from 10 to 50ppm of Lorcaserin 
HCL. The calibration curve was constructed by area against 
concentration of drug and it is shown in fig.5. The 
Correlation coefficient for area verses concentration of 
analyte was calculated and is presented in Table 7. 
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Robustness: 
Robustness of this method was determined by deliberate 
small change in flow rate (±2units) and wavelength (±2nm) 
from data to calculated SD and %RSD result shown in Table 
8 and 9. 
Limit of Detection and Limit of Quantification: 
The LOD and LOQ were separately determined based on 
standard deviation from accuracy and slope from Linearity. 
The results shown in Table 10. 
Forced degradation studies: 
Forced degradation studies are applied by different ways 
like Acidic, Base/Alkaline, Oxidative, Photolytic and Thermal 
degradation. For this Concentration of standard solution was 
made and used for degradation at different conditions 
injected in HPLC and chromatogram was recorded. The 
result of degradation was shown in Table 11.  
RESULTS: 
Table-1: Result of HPLC Assay for Lorcaserin HCL 
Name of Drug Composition 
(ppm) 
% Assay 
Bulk Formulation 
Lorcaserin HCL 30 100.33 99.89 
 
Table-2: System suitability studies of Lorcaserin HCL 
Lorcaserin HCL 
Property Observed values 
Retention time 5.108 
Resolution (Rs) 0.00 
Theoretical plates (N) 8095 
Tailing factor/Asymmetry factor (T) 1.17 
 
 
  
Table-3: Linearity results for Lorcaserin HCL 
Drug Lorcaserin HCL 
Conc. (ppm) 10 20 30 40 50 
Area 426768 886084 1288349 1691790 2127452 
Regression  equation y = 42071x + 21966 
Correlation (R2) 0.9995 
Slope (m) 42071 
Intercept (c) 21966 
 
Table-4: Accuracy and Recovery data for Lorcaserin HCL 
Lorcaserin HCL 
% 
Composition 
Sample amount 
(ppm) 
Amount added 
(ppm) 
Final Volume 
(ppm) 
 
Area 
% 
Recovery 
% Mean 
recovery 
50% 20 10 30 1279472 100.78  
 
100.65 
20 10 30 1281955 101.37 
20 10 30 1275310 99.79 
100% 20 20 40 1683842 98.45  
 
98.84 
20 20 40 1691327 99.34 
20 20 40 1686175 98.72 
150% 20 30 50 2117367 99.98  
 
100.34 
20 30 50 2125830 100.65 
20 30 50 2122413 100.38 
 
Table-5: Statistical data of Accuracy and Recovery for Lorcaserin HCL 
Lorcaserin HCL 
% Composition Mean area std. Mean area sample SD %RSD 
50% 1288349 1278912 3357.667 0.26 
100% 1691790 1687115 3829.952 0.23 
150% 2127452 2121870 4257.550 0.20 
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Table-6: Precision results for Lorcaserin HCL 
Lorcaserin HCL 
Sample No. Interday Precision (area) Intraday Precision (area) 
1 1288349 1288349 
2 1288804 1288804 
3 1282054 1282054 
4 1283639 1286095 
5 1284512 1290500 
6 1290410 1292806 
Mean 1286295 1288101 
SD 3336.67 3715.863 
%RSD 0.26% 0.29% 
 
Table-7: Ruggedness results for Lorcaserin HCL 
Drug Lorcaserin HCL 
Conc. (ppm) 10 20 30 40 50 
Area 422048 882827 1282843 1697369 2123613 
Regression  equation y = 42177x + 16438 
Correlation (R2) 0.9995 
Slope (m) 42177 
Intercept (c) 16438 
 
Table-8: Robustness data for Lorcaserin at different flow rate and wavelength 
Lorcaserin HCL 
Level Retention time Tailing factor 
Change in Flow rate (ml/min)   
-1(0.7ml) 5.861 1.21 
0(0.8ml) 5.164 1.18 
+1(0.9ml) 4.605 1.19 
Change in Wavelength (nm) Retention time Tailing factor 
-2(220nm) 5.178 1.20 
0(222nm) 5.164 1.18 
+2(224nm) 5.153 1.19 
 
Table-9: Statistical data of Robustness for Lorcaserin HCL 
Lorcaserin HCL 
Change in Flow rate (ml/min) Conc. (ppm) Area Mean SD %RSD 
-1(0.7ml) 20 889961  
 
886478 
 
 
3304.14 
 
 
0.37 
0(0.8ml) 20 886084 
+1(0.9ml) 20 883388 
 
Change in Wavelength (nm) Conc. (ppm) Area Mean SD %RSD 
-2(220nm) 20 884240  
 
885393 
 
 
1005.07 
 
 
0.11 
0(222nm) 20 886084 
+2(224nm) 20 885855 
 
Table-10: LOD and LOQ data for Lorcaserin HCL 
Sr.No. Drug LOD (µg/ml) LOQ (µg/ml) 
1 Lorcaserin HCL 0.263 0.798 
 
Table-11: Stability data for Lorcaserin HCL 
Sr.No. Stress condition Retention 
time 
Area of Peak Degraded up to % Actual % 
degradation 
1 Standard Drug 5.229 2127452 -- -- 
2 Acidic (0.1N HCL) 5.145 1993666 93.71 6.29 
3 Alkaline (0.1N NaOH) 5.148 1985610 93.33 6.67 
4 Oxidation (3% H2O2) 5.148 2051548 96.43 3.57 
5 Photolytic 5.148 2063088 96.97 3.03 
6 Thermal 5.143 2079926 97.77 2.23 
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Table-12: Characteristic parameters of Lorcaserin HCL for proposed RP-HPLC method 
Parameters  RP-HPLC 
Calibration range (µg/ml) 10-50 of Lorcaserin HCL 
Detection Wavelength 222nm 
Mobile Phase Methanol:10mM KH2PO4 Buffer (70:30) pH:3 
Flow rate 0.8ml/min 
Retention time 5.108 min 
Temperature Ambient 
Pressure 10-11MPa 
Regression equation (Y) Y= mx+c 
Slope (m) 42071 
Intercept (c) 21966 
Correlation coefficient (r2) 0.9995 
Interday Precision (%RSD) 0.26% 
Intraday Precision (%RSD) 0.29% 
Limit of detection (mcg/ml) 0.263 
Limit of quantification (mcg/ml)  0.798 
 
 
Fig-2: Wavelength detection of Lorcaserin hydrochloride. 
 
Mobile phase: Methanol: Buffer (70:30) pH:3, Run time: 8.22min 
Flow Rate Time Area Resolution T.PlateNum Asymmetry 
0.8ml/min 5.108 1136912 0.00 8095 1.17 
Fig-3: Optimized chromatogram for Lorcaserin HCL at (222nm) 
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Fig-4: Linearity graph of Lorcaserin HCL 
 
 
Fig-5: Ruggedness graph of Lorcaserin HCL 
DISCUSSION: 
In HPLC method, HPLC conditions were optimized and 
adequate elution of compound observed. The main objective 
of this study was to develop sensitive and rapid RP-HPLC 
method for determination and analysis of Lorcaserin HCL in 
bulk and Pharmaceutical dosage form by using Cosmosil C18 
(250nm×4.6ID, Particle Size: 5 Micron) Column with mobile 
phase Methanol:10mM KH2PO4 Buffer (70:30) pH:3. A flow 
rate 0.8ml/min with UV detection at 222nm. The retention 
time for Lorcaserin HCL was found to be 5.108 min.  
A good linear relationship (r2 = 09995) was observed 
between the concentration of Lorcaserin HCL and respective 
peak areas in range of 10-50ppm. To analyse tablet 
formulations, RP-HPLC method has been developed. 
Lorcaserin HCL contained tablet was analyzed as per the 
procedure described above. The mean recoveries were 
found in the range of 98%- 102%.  The low %RSD values (≤ 
2) indicated that method was accurate and precise. In 
stability study Lorcaserin hydrochloride undergoes different 
parameters, comparatively more degradation was found 
with alkaline and acidic shows that the degradation product 
does not interfere with analytical determination of 
Lorcaserin HCL in Pharmaceutical dosage form. The 
degradation of drug was found to be within acceptance 
criteria. 
CONCLUSION: 
A simple, sensitive, rapid, linear, accurate, precise and 
stabilized method has been developed and validated for 
determination of Lorcaserin HCL in bulk and tablet 
formulation it is suitable for routine analysis work. 
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